Press launch MHRA approves GLP –one receptor agonist semaglutide to scale back threat of great coronary heart challenges in obese or overweight Grown ups Semaglutide is the primary weight-loss drug accepted in the united kingdom as being a preventative treatment method for those with founded cardiovascular diseaseNumerous current scientific tests